Clinical Trial

A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a double-blind, placebo-controlled study in adults with a diagnosis of moderate-to-severe chronic plaque psoriasis to test the efficacy and safety of piclidenoson in this patient population.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-14.
Trial Details
NCT Number NCT06643260
Lead Sponsor Can-Fite BioPharma
Conditions Plaque Psoriasis
Enrollment 705 participants
Start Date 2025-06
Primary Completion 2027-12 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-04-29